- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 174-188 of
247 results
2018 Exhibit: Ex 2018 Weick 2002
Document
IPR2018-01714, No. 2018 Exhibit - Ex 2018 Weick 2002 (P.T.A.B. Dec. 18, 2018)
|
|
Cite Document
1031 Exhibit: Moreira et al, Thalidomide exerts its inhibitory action on tumor necros...
Document
IPR2018-01714, No. 1031 Exhibit - Moreira et al, Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation, J Exp Med, 1771675 1680 1993 (P.T.A....
|
|
Cite Document
1042 Exhibit: Morgan J et al, Overall survival with dexamethasone in phase III mult...
Document
IPR2018-01714, No. 1042 Exhibit - Morgan J et al, Overall survival with dexamethasone in phase III multiple myeloma trials after adjustment for cross over to lenalidomide, Haematologica 93s1, A...
|
|
Cite Document
1024 Exhibit: Cytovene¿¿ IV, Physicians Desk Reference 2623 2629 54th ed 2000
Document
IPR2018-01714, No. 1024 Exhibit - Cytovene¿¿ IV, Physicians Desk Reference 2623 2629 54th ed 2000 (P.T.A.B. Sep. 12, 2018)
|
|
Cite Document
2010 Exhibit: Ex 2010 Zangari 2001
Document
IPR2018-01714, No. 2010 Exhibit - Ex 2010 Zangari 2001 (P.T.A.B. Dec. 18, 2018)
|
|
Cite Document
1056 Exhibit: 21 CFR 300 499 as of April 1, 2001
Document
IPR2018-01714, No. 1056 Exhibit - 21 CFR 300 499 as of April 1, 2001 (P.T.A.B. Sep. 12, 2018)
|
|
Cite Document
1053 Exhibit: Barlogie et al, Extended survival in advanced and refractory multiple ...
Document
IPR2018-01714, No. 1053 Exhibit - Barlogie et al, Extended survival in advanced and refractory multiple myeloma after single agent thalidomide identification of prognostic factors in a phase 2 st...
|
|
Cite Document
1030 Exhibit: Bilgrami et al, Dexamethasone, paclitaxel, etoposide, cyclophospham...
Document
IPR2018-01714, No. 1030 Exhibit - Bilgrami et al, Dexamethasone, paclitaxel, etoposide, cyclophosphamide d TEC and G CSF for stem cell mobilisation in multiple myeloma, Bone Marrow Transp...
|
|
Cite Document
1028 Exhibit: US Patent No 6,281,230 the 230 Patent
Document
IPR2018-01714, No. 1028 Exhibit - US Patent No 6,281,230 the 230 Patent (P.T.A.B. Sep. 12, 2018)
|
|
Cite Document
1004 Exhibit: Sampaio et al, Thalidomide selectively inhibits tumor necrosis factor a...
Document
IPR2018-01714, No. 1004 Exhibit - Sampaio et al, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes, J Exp Med, 1733 699 703 1991 (P.T.A...
|
|
Cite Document
2012 Exhibit: Ex 2012 Gordon
Document
IPR2018-01714, No. 2012 Exhibit - Ex 2012 Gordon (P.T.A.B. Dec. 18, 2018)
|
|
Cite Document
1032 Exhibit: Barlogie et al, Effective treatment of advanced multiple myeloma refra...
Document
IPR2018-01714, No. 1032 Exhibit - Barlogie et al, Effective treatment of advanced multiple myeloma refractory to alkylating agents, N Engl J Med, 310211353 1356 1984 (P.T.A.B. Sep. 12, 2018...
|
|
Cite Document
1038 Exhibit: Lacy, MQ, et al, Long term Results of Response to Therapy, Time to P...
Document
IPR2018-01714, No. 1038 Exhibit - Lacy, MQ, et al, Long term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed M...
|
|
Cite Document
1048 Exhibit: Oken et al, Contribution of Prednisone to the Effectiveness of Hexam...
Document
IPR2018-01714, No. 1048 Exhibit - Oken et al, Contribution of Prednisone to the Effectiveness of Hexamethylmelamine in Multiple Myeloma, Cancer Treatment Reports, 71807 811 1987 (P.T.A.B...
|
|
Cite Document
2002 Exhibit: Ex 2002 August 2018 Guide
Document
IPR2018-01714, No. 2002 Exhibit - Ex 2002 August 2018 Guide (P.T.A.B. Dec. 18, 2018)
|
|
Cite Document
